Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Corlopam fenoldopam dopamine DA1 agonist regulatory update

ELN's Elan Pharmaceuticals division (South San Francisco, Calif.) said it received

Read the full 119 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE